Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday

Key Points

• Achieve Life Sciences will report Q1 2026 results before the market opens on Tuesday, May 12, 2026, and analysts expect earnings of ($0.30) per share (the company posted ($0.28) last quarter).
• Shares traded up about 1.1% to $4.44 midday with a market cap of $236.3M, and analysts have a consensus "Buy" rating with a consensus price target of $14.67.
• Institutional investors have materially increased positions—Franklin Resources, Vanguard and Millennium among the largest recent buyers—leaving roughly 33.5% of the stock owned by institutions.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its quarterly earnings data on Tuesday, March 24th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Trading Up 1.1%

NASDAQ:ACHV traded up $0.05 during midday trading on Tuesday, hitting $4.44. The stock had a trading volume of 282,187 shares, compared to its average volume of 926,465. Achieve Life Sciences has a one year low of $2.00 and a one year high of $6.03. The company has a market capitalization of $236.34 million, a price-to-earnings ratio of -3.42 and a beta of 2.25. The stock has a 50-day moving average of $3.92 and a 200 day moving average of $4.41. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.52.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ACHV shares. HC Wainwright reissued a "buy" rating and issued a $12.00 price objective on shares of Achieve Life Sciences in a research note on Thursday, April 16th. Weiss Ratings raised Achieve Life Sciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. Finally, Canaccord Genuity Group set a $13.00 price objective on Achieve Life Sciences and gave the stock a "buy" rating in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $14.67.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its position in shares of Achieve Life Sciences by 18,747.4% in the 4th quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company's stock worth $21,715,000 after purchasing an additional 4,346,011 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Achieve Life Sciences by 14.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company's stock worth $7,755,000 after purchasing an additional 311,925 shares in the last quarter. Millennium Management LLC boosted its position in shares of Achieve Life Sciences by 472.3% in the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company's stock worth $6,755,000 after purchasing an additional 1,121,614 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Achieve Life Sciences in the 2nd quarter worth $2,652,000. Finally, Marshall Wace LLP boosted its position in shares of Achieve Life Sciences by 31.5% in the 4th quarter. Marshall Wace LLP now owns 1,019,281 shares of the biopharmaceutical company's stock worth $5,066,000 after purchasing an additional 244,428 shares in the last quarter. 33.52% of the stock is currently owned by hedge funds and other institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc NASDAQ: ACHV is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.